JP2003530124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530124A5 JP2003530124A5 JP2001575639A JP2001575639A JP2003530124A5 JP 2003530124 A5 JP2003530124 A5 JP 2003530124A5 JP 2001575639 A JP2001575639 A JP 2001575639A JP 2001575639 A JP2001575639 A JP 2001575639A JP 2003530124 A5 JP2003530124 A5 JP 2003530124A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- polynucleotide
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 75
- 229920001184 polypeptide Polymers 0.000 description 74
- 102000004196 processed proteins & peptides Human genes 0.000 description 74
- 108091033319 polynucleotide Proteins 0.000 description 47
- 102000040430 polynucleotide Human genes 0.000 description 47
- 239000002157 polynucleotide Substances 0.000 description 47
- 150000001413 amino acids Chemical group 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 7
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000001368 germline stem cell Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54377400A | 2000-04-05 | 2000-04-05 | |
| US09/543,774 | 2000-04-05 | ||
| US21573300P | 2000-06-28 | 2000-06-28 | |
| US60/215,733 | 2000-06-28 | ||
| US75756201A | 2001-01-09 | 2001-01-09 | |
| US09/757,562 | 2001-01-09 | ||
| US26661401P | 2001-02-05 | 2001-02-05 | |
| US60/266,614 | 2001-02-05 | ||
| PCT/US2001/011208 WO2001077169A2 (fr) | 2000-04-05 | 2001-04-05 | Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530124A JP2003530124A (ja) | 2003-10-14 |
| JP2003530124A5 true JP2003530124A5 (fr) | 2008-06-19 |
Family
ID=27499020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001575639A Withdrawn JP2003530124A (ja) | 2000-04-05 | 2001-04-05 | 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1268543A2 (fr) |
| JP (1) | JP2003530124A (fr) |
| AU (1) | AU5904101A (fr) |
| CA (1) | CA2405104A1 (fr) |
| WO (1) | WO2001077169A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20050130145A1 (en) * | 2001-10-03 | 2005-06-16 | Henry Yue | Secreted proteins |
| PT2157192E (pt) | 2003-10-10 | 2013-11-28 | Deutsches Krebsforsch | Composições para diagnóstico e terapia de doenças associadas com a expressão aberrante de futrinas (r-espondinas) |
| BRPI0507168A (pt) * | 2004-01-27 | 2007-06-26 | Nuvelo Inc | fator proliferativo gastrointestinal e aplicações do mesmo |
| WO2007030290A2 (fr) * | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Ligands cristine/r-spondine actifs dans la voie de signalisation wnt et methodes, compositions et kits associes |
| US20090118176A1 (en) * | 2005-10-07 | 2009-05-07 | Emtage Peter C R | Stem Cell Factor-Like Protein Scfa1 and Uses Thereof |
| MX2009003229A (es) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
| MX2009003726A (es) | 2006-10-20 | 2009-04-22 | Deutsches Krebsforsch | R-espondinas como moduladores de la angiogenesis y vasculogenesis. |
| WO2008075796A1 (fr) * | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | Agent pour encourager la récupération après une déplétion de globule sanguin |
| AU2008270972B2 (en) | 2007-07-02 | 2013-10-24 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| RU2555545C2 (ru) | 2009-02-03 | 2015-07-10 | Конинклейке Недерландсе Академи Ван Ветенсаппен | Культуральная среда для эпителиальных стволовых клеток и органоидов, содержащих указанные стволовые клетки |
| EP2412800A1 (fr) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir |
| WO2010121923A1 (fr) | 2009-04-15 | 2010-10-28 | Deutsches Krebsforschungszentrum | Inhibition de la rspondine-3 dans des troubles osseux |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| CA2867487C (fr) * | 2012-03-21 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Isolement et utilisation de cellules stromales suppressives derivees d'un organe lymphoide humain |
| US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| AU2015317986A1 (en) | 2014-09-16 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| CN108607101A (zh) * | 2018-05-04 | 2018-10-02 | 广西中医药大学附属瑞康医院 | Zip1基因在制备抑制骨髓间充质干细胞凋亡的产品中的应用 |
| CN111420034A (zh) * | 2019-01-08 | 2020-07-17 | 上海莱馥医疗科技有限公司 | 一种用于治疗银屑病的混合干细胞制剂及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001527403A (ja) * | 1997-04-25 | 2001-12-25 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| EP1169333A1 (fr) * | 1999-03-19 | 2002-01-09 | Human Genome Sciences, Inc. | Proteines humaines secretees (49) |
| CN1297930A (zh) * | 1999-11-29 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人凝血栓蛋白30和编码这种多肽的多核苷酸 |
| EP1572987A4 (fr) * | 2000-02-03 | 2005-11-30 | Nuvelo Inc | Acides nucleiques et polypeptides |
-
2001
- 2001-04-05 EP EP01932523A patent/EP1268543A2/fr not_active Withdrawn
- 2001-04-05 AU AU5904101A patent/AU5904101A/xx active Pending
- 2001-04-05 JP JP2001575639A patent/JP2003530124A/ja not_active Withdrawn
- 2001-04-05 CA CA002405104A patent/CA2405104A1/fr not_active Abandoned
- 2001-04-05 WO PCT/US2001/011208 patent/WO2001077169A2/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530124A5 (fr) | ||
| JP2004267216A5 (fr) | ||
| JP2882775B2 (ja) | ヒトーグリア由来神経突起因子 | |
| JP2020534828A5 (fr) | ||
| JP2002521055A5 (fr) | ||
| RU2008117631A (ru) | Белки шелка | |
| JP2002502589A5 (fr) | ||
| JP2003516731A5 (fr) | ||
| JP2002518010A5 (fr) | ||
| JP2005052158A5 (fr) | ||
| CA2383424A1 (fr) | Nouvelles molecules b7-4 et leurs utilisations | |
| JP2002516103A5 (fr) | ||
| CA2279836A1 (fr) | Polynucleotides codant la proexendine, et procedes et utilisations correspondants | |
| JP2008545436A5 (fr) | ||
| JP2002500043A5 (fr) | ||
| EP3492491A1 (fr) | Mutant de mg53, son procédé de préparation et ses utilisations | |
| CA2146328A1 (fr) | C-c ckr-1, recepteur c-c chemokine | |
| JP2011509093A5 (fr) | ||
| JP2002506625A5 (fr) | ||
| Klein et al. | Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes | |
| EP0851030A1 (fr) | PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT | |
| JP2020508058A (ja) | 新規マイナー組織適合性抗原およびそれらの使用 | |
| Ohmachi et al. | Molecular organization of developmentally regulated Dictyostelium discoideum ubiquitin cDNAs | |
| JP2004505640A5 (fr) | ||
| JP2005507240A5 (fr) |